Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women

AIDS

Volumn 23, Issue 12, 2009, Pages 1531-1538

  Nel, Annalene M ^a   Coplan, Paul ^b   Van De Wijgert, Janneke H ^c,d   Kapiga, Saidi H ^e,f   Von Mollendorf, Claire ^g   Geubbels, Eveline ^c,d   Vyankandondera, Joseph ^c,h   Rees, Helen V ^g   Masenga, Gileard ^e   Kiwelu, Ireen ^e   Moyes, Jocelyn ^g   Smythe, Shanique C ^a  

^a INTERNATIONAL PARTNERSHIP FOR MICROBICIDES   (United States)

^b PFIZER INC   (United States)

^c Projet Ubuzima   (Rwanda)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e Kilimanjaro Reproductive Health Program   (Tanzania)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^g UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^h Central Hospital of Kigali   (Rwanda)

Author keywords

Dapivirine; HIV; HIV prevention; Microbicide; Vaginal gel

Indexed keywords

DAPIVIRINE; PLACEBO;

ABDOMINAL ABSCESS; ABDOMINAL PAIN; ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; COLPOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEMALE GENITAL PRURITUS; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOTIC THROMBOCYTOPENIC PURPURA; URINE ODOR; UTERINE CERVIX DISEASE; UTERINE SPASM; UTERUS MYOMA; VAGINA CANDIDIASIS; VAGINA DISCHARGE;

ADMINISTRATION, INTRAVAGINAL; ADOLESCENT; ADULT; ANTI-HIV AGENTS; CERVIX UTERI; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HUMANS; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SATISFACTION; PYRIMIDINES; VAGINA; VAGINAL CREAMS, FOAMS, AND JELLIES; VULVA; YOUNG ADULT;

EID: 68649117176     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832c413d     Document Type: Article

References (16)

1. UNAIDS/WHO. AIDS Epidemic Update: December 2007. UNAIDS, Geneva; 2007. UNAIDS/07.27E/JC1322E. ISBN 978-92-9-173621-8. http://data.unaids.org/pub/ EPISIides/2007/2007-epiupdate-en.pdf.
2. Kilmarx PH, van de Wijgert JH, Chaikummao S, Jones HE, Limpakarnjanarat K, Friedland BA, et al. Safety and acceptability of the candidate microbicide Carraguard in Thai women: findings from a phase II clinical trial. J Acquir Immune Defic Syndr 2006; 43:327-334.
3. Morrow K, Rosen R, Richter L, Emans A, Forbes A, Day J, et al. The acceptability of an investigational vaginal microbicide, PRO 2000 gel, among women in a phase I clinical trial. J Womens Health (Larchmt) 2003; 12:655-666.
4. Trottier S, Omar RE, Désormeaux A, Drouin J, Gagnon MT, Vezina F et al. Safety, tolerance and acceptability of the Invisible Condom and its vaginal applicator in healthy women and their male sexual partners. Contraception 2007; 76:117-125.
5. Malonza IM, Mirembe F, Nakabiito C, Odusoga LO, Osinupebi OA, Hazari K, et al. Expanded phase 1 safety and acceptability study of 6% cellulose sulfate vaginal gel. AIDS 2005; 19:2157-2163.
6. Bentley ME, Fullem AM, Tolley EE, Kelly CW, Jogelkar N, Srirak N, et al. Acceptability of a microbicide among women and their partners in a 4-country phase I trial. Am J Public Health 2004; 94:1159-1164.
7. D'Cruz OJ, Uckun FM. Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des 2004; 10:315-336.
8. 14C] dapivirine for 7 days. Antimicrob Agents Chemother 2008; 52:909-914.
9. Jespers VA, Van Roey JM, Beets Gl, Buvé AM. Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers. J Acquir Immune Defic Syndr 2007; 44:154-158.
10. Woolfson AD, Malcolm RK, Morrow RJ, Toner CF, McCullagh SD. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int J Pharm 2006; 325:82-89.
11. Malcolm RK, Woolfson AD, Toner CF, Morrow RJ, McCullagh SD. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother 2005; 56:954-956.
12. Van Herrewege Y, Michiels J, Van Roey J, Fransen K, Kestens L, Balzarini J, et al. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother 2004; 48:337-339.
13. Di Fabio S, Van Roey J, Giannini G, Van Den Mooter G, Spada M, Binelli A, et al. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the nonnucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS 2003; 17:1597-1604.
14. Schwartz JL, Ballagh SA, Kwok C, Mauck CK, Weiner DH, Rencher WF, et al. Fourteen-day safety and acceptability study of the universal placebo gel. Contraception 2007; 75:136-141.
15. Haddy TB, Rana SR, Castro O. Benign ethnic neutropenia: what is a normal absolute neutrophil count? J Lab Clin Med 1999; 133:15-22.
16. Karita E, Ketter N, Price M, Kayitenkore K, Kaleebu P, Nanvubya A, et al. CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa. PLoS One 2009; 4:1-14.